Annie Luetkemeyer
Overview
Explore the profile of Annie Luetkemeyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
3301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McGourty C, Ung D, Clark M, Nguyen J, McDonell C, Luetkemeyer A, et al.
Int J Drug Policy
. 2025 Mar;
139:104768.
PMID: 40088600
Background: Despite simplified hepatitis C virus (HCV) treatment algorithms, insurance-related barriers prevent same-day HCV treatment upon diagnosis in the US. We assessed how direct partnerships with a pharmacy team facilitated...
2.
Ortega-Villa A, Hynes N, Levine C, Yang K, Wiley Z, Jilg N, et al.
Open Forum Infect Dis
. 2023 Jun;
10(6):ofad290.
PMID: 37383244
Background: Clinical trials initiated during emerging infectious disease outbreaks must quickly enroll participants to identify treatments to reduce morbidity and mortality. This may be at odds with enrolling a representative...
3.
Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden L, et al.
Res Sq
. 2023 May;
PMID: 37205592
Vaccine protection against COVID-19 wanes over time and has been impacted by the emergence of new variants with increasing escape of neutralization. The COVID-19 Variant Immunologic Landscape (COVAIL) randomized clinical...
4.
Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A, et al.
N Engl J Med
. 2020 May;
383(19):1813-1826.
PMID: 32445440
Background: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. Methods: We conducted a...
5.
Naggie S, Fierer D, Hughes M, Kim A, Luetkemeyer A, Vu V, et al.
Clin Infect Dis
. 2019 Jun;
69(3):514-522.
PMID: 31220220
Background: Current guidelines for the management of hepatitis C virus (HCV) infections provide varying recommendations for the optimal treatment of acute HCV infections. There are limited data from small cohort...
6.
Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, et al.
Infect Dis Clin North Am
. 2018 May;
32(2):293-311.
PMID: 29778257
The United States has national plans for the elimination of hepatitis C virus but much of US health care is organized on the state level and requires local solutions. This...
7.
Wyles D, Wedemeyer H, Ben-Ari Z, Gane E, Hansen J, Jacobson I, et al.
Hepatology
. 2017 Jul;
66(6):1794-1804.
PMID: 28688129
Conclusion: Grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, for 16 or 24 weeks was safe and highly effective in participants with HCV infection who had previously failed NS5A inhibitor-containing...
8.
Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, et al.
J Interferon Cytokine Res
. 2017 Mar;
37(3):103-111.
PMID: 28282271
To evaluate the efficacy and safety of pegylated interferon-lambda-1a (Lambda)/ribavirin (RBV)/daclatasvir (DCV) for treatment of patients coinfected with chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Treatment-naive patients...
9.
Marks K, Kitch D, Chung R, Hadigan C, Andersen J, Tien P, et al.
J Acquir Immune Defic Syndr
. 2014 Feb;
65(3):345-9.
PMID: 24525470
: Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment. In this multicenter, single-arm pilot study, adult, HIV/HCV genotype 1-coinfected previous nonresponders to peginterferon/ribavirin (PegIFN/RBV) with homeostatic...
10.
Nahid P, Saukkonen J, Mac Kenzie W, Johnson J, Phillips P, Andersen J, et al.
Am J Respir Crit Care Med
. 2011 Jul;
184(8):972-9.
PMID: 21737585
The Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. The goals were to assess...